Atrial Fibrillation and Hypertension: “Quo Vadis”

(E-pub Ahead of Print)

Author(s): McCall Walker, Paras Patel, Osung Kwon, Ryan J Koene, Daniel A. Duprez, Younghoon Kwon*

Journal Name: Current Hypertension Reviews

Become EABM
Become Reviewer


Hypertension is one of the most well-established risk factors for atrial fibrillation. Long-standing untreated hypertension leads to structural remodeling and electrophysiologic alterations causing an atrial myopathy that forms a vulnerable substrate for the development and maintenance of atrial fibrillation. Hypertension-induced hemodynamic, inflammatory, hormonal, and autonomic changes all appear to be important contributing factors. Furthermore, hypertension is also associated with several atrial fibrillation-related comorbidities. As such, hypertension may represent an important target for therapy in atrial fibrillation. Clinicians should be aware of pitfalls of the blood pressure measurement in atrial fibrillation. While the auscultatory method is preferred, the use of automated devices appears to be an acceptable method in the ambulatory setting. There are pathophysiologic bases and emerging clinical evidence suggesting the benefit of renin-angiotensin system inhibition in risk reduction of atrial fibrillation development particularly in patients with left ventricular hypertrophy or left ventricular dysfunction. A better understanding of hypertension’s pathophysiologic link to atrial fibrillation may lead to the development of novel therapies for the primary prevention of atrial fibrillation. Finally, future studies are needed to address optimal blood pressure goal to minimize the risk of atrial fibrillation-related complications.

Keywords: Atrial Fibrillation, Hypertension, Blood Pressure, Renin-angiotensin System, Atrial Remodeling, Autonomic Dysfunction, Chronic Inflammation

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1573402115666190502142824

Article Metrics

PDF: 10